Shattuck Labs to Participate in Upcoming December Investor Conferences

Core Insights - Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for inflammatory and immune-mediated diseases [1][4] - The company will participate in multiple investor conferences in December 2025, including the Piper Sandler 37 Annual Healthcare Conference and the Evercore ISI 8 Annual HealthCONx Conference [1][2] Conference Details - The Piper Sandler 37 Annual Healthcare Conference will feature a presentation by CEO Taylor Schreiber on December 2, 2025, at 10:10 AM EST in New York, NY [2] - The Evercore ISI 8 Annual HealthCONx Conference will include a fireside chat with CEO Taylor Schreiber on December 4, 2025, at 8:20 AM EST in Coral Gables, FL [2] - Replays of the presentations will be available on the company's website for up to 30 days following the events [2] Product Development - SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to block the DR3/TL1A pathway, showing high affinity binding and superior activity compared to TL1A antibodies [3] - SL-325 is currently in a Phase 1 clinical trial and has demonstrated a favorable safety profile in non-human primates [3][4] - The company aims to develop SL-325 as a treatment for inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases [4]